RE:RE:RE:Tic..Tac..FDA V4.0 and Sales at any time now Insiders know🚀Good comment see Topper00 the Fudster
“We are delighted to achieve CE mark certification and will introduce the enhanced capabilities of the new version to European cardiologists and healthcare providers,” said Ventripoint President and CEO, Hugh MacNaught. “This is a key step in our commercialization plan as we continue to advance our technology leadership and impact by advancing the state-of-the-art in echocardiography. The advances introduced in VMS+4.0 provide clinicians with the potential to image a broader range of patients which expands our market opportunity. This engineering breakthroughs in this latest version of VMS+ provide healthcare providers with a powerful tool that delivers accurate and reliable cardiac output measurements in a more efficient manner, and without the restrictions associated with MRI.” VMS+V4.0 will be marketed as a premium product in Europe to complement our base product V3.2. VMS+ 4.0 has already a Medical Device License in Canada, and is under review by US-FDA. VMS+ V3.2 is being used by leading hospitals in the U.S., E.U., U.K. and Canada.
Very good news (Tic..Tac..V4.0 + FDA V4.0 and Sales at any time now Insiders know!) VMS+V4.0 will be marketed as a premium product in Europe to complement our base product V3.2. VMS+ 4.0 has already a Medical Device License in Canada, and is under review by US-FDA. VMS+ V3.2 is being used by leading hospitals in the U.S., E.U., U.K. and Canada.Maybe some news ! The BEST automation and analysis of the PLANET GEN3EHO Now That V4.0 est ok pour le Canada & On Ascend website https://ascendcv.com/ Interesting on Linkedin Angio Consult GmbH 8 hours ago Next stop: #TCT2024 in Washington, DC! Get ready to connect with us at one of the most anticipated cardiology events of the year. We're thrilled to share insights, learn from industry leaders, and showcase how AngioConsult is pushing the boundaries in cardiovascular care. Join us to discover the latest advancements and collaborate on future innovations. Let’s shape the future of cardiology together! #vpt, 1
@nicolaosK 24 hospitals is a great place to start! 14
@cardinal very nice validation. sales news next up 12
@yudi Post on Linkedin Richard Simpson 48 minutes ago Ventripoint Diagnostics Ltd. receives EU CE Mark for its Next Generation Echocardiography AI product. Whole heart output metrics with particular accuracy for right ventricle, automated image processing, magnet https://lnkd.in/gUfWqkJX Toronto, Ontario – TheNewswire - October 24, 2024 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTCQB:VPTDF) a leader in whole heart analysis technology, is pleased to announce CE Mark certification for its latest offering, VMS+4.0. This marks a significant milestone for Ventripoint as it continues to innovate and provide cutting-edge solutions to healthcare professionals worldwide.
The certification will allow Ventripoint to engage in the next steps of country-specific entrance of VMS+4.0 in the European Union (EU) and other geographies that recognize CE marking. VMS+4.0 offers a significant improvement in user experience through the automation of the image processing steps. This streamlined workflow leads to a significant reduction in operator time without compromising the accuracy of the measurements. Additionally, this release is optimized to work seamlessly with Ventripoint’s magnet-free sensors, further enhancing efficiency and ease of use.
“We are delighted to achieve CE mark certification and will introduce the enhanced capabilities of the new version to European cardiologists and healthcare providers,” said Ventripoint President and CEO, Hugh MacNaught. “This is a key step in our commercialization plan as we continue to advance our technology leadership and impact by advancing the state-of-the-art in echocardiography. The advances introduced in VMS+4.0 provide clinicians with the potential to image a broader range of patients which expands our market opportunity. This engineering breakthroughs in this latest version of VMS+ provide healthcare providers with a powerful tool that delivers accurate and reliable cardiac output measurements in a more efficient manner, and without the restrictions associated with MRI.”
VMS+V4.0 will be marketed as a premium product in Europe to complement our base product V3.2. VMS+ 4.0 has already a Medical Device License in Canada, and is under review by US-FDA. VMS+ V3.2 is being used by leading hospitals in the U.S., E.U., U.K. and Canada.